UCB SA (OTCMKTS:UCBJF) Short Interest Up 59.5% in November

UCB SA (OTCMKTS:UCBJF) was the target of a significant growth in short interest in November. As of November 15th, there was short interest totalling 643,700 shares, a growth of 59.5% from the October 31st total of 403,500 shares. Based on an average daily volume of 200 shares, the short-interest ratio is presently 3,218.5 days.

UCB Stock Performance

UCB stock remained flat at $174.00 during midday trading on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78. UCB has a twelve month low of $73.54 and a twelve month high of $194.76. The firm has a fifty day moving average price of $180.83 and a two-hundred day moving average price of $160.59.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.